The global vaccine market is diverse while facing a plethora of novel developments. Genetic modification (GM) techniques facilitate the design of 'smarter' vaccines. For many of the major infectious diseases of humans, like AIDS and malaria, but also for most human neoplastic disorders, still no vaccines are available. It may be speculated that novel GM technologies will significantly contribute to their development. While a promising number of studies is conducted on GM vaccines and GM vaccine technologies, the contribution of GM technology to newly introduced vaccines on the market is disappointingly limited.
Introduction
Ever since the discovery by Edward Jenner, more than two centuries ago, that vaccinia virus could be used to protect people from variola, vaccines have been of utmost importance in fighting infectious diseases [1] , as they are the most cost effective tools for the prevention of infectious diseases. To date several types of vaccines are available, including live-attenuated, inactivated, subunit or split, toxoid, conjugate, DNA, and recombinant vectored vaccines [2] . While conventional vaccines, like live-attenuated or inactivated wild-type, have successfully protected vaccinees from various infectious diseases over the years, they are not available for most infectious diseases and for those who cannot afford them.
Conventional vaccine production methods, which predominantly use viruses and bacteria or their products, produced with classical production methods, are labour intensive, expensive, and time consuming, while some of the desired antigens cannot be produced in this way [3] . Furthermore, highly virulent pathogens can only be produced under expensive special safety conditions, while attenuated agents may have a tendency of reverting to their pathogenic form and can usually only be used in fully competent individuals [4] .
To overcome the challenges of traditional vaccine production, the development and use of novel generations of vaccines, like those based on GM technologies, are being considered more and more frequently. The advent of these novel technologies may also be expected to create opportunities for the development of vaccines targeting new indications and/or application fields. Since there are many major indications for which no or only unsatisfactory vaccines are available, like AIDS, malaria, and tuberculosis, the exploitation of novel technologies, like the use of vector-based vac-cine candidates or vector-based production of protective antigens, may eventually allow us to fill the gap of this unmet medical need. To date several vaccines for humans, based on GM technologies have been licensed (for review see e.g. [5] [6] [7] [8] ) and a lot of candidates are in the pipeline.
An interesting approach for vaccine development based on GM technology is the use of vectors, which carry selected genes encoding antigens that induce protective immunity. They can either be used as vaccines proper, or for the production of antigens that are incorporated in vaccines. The present paper only deals with vectors that are actually used as vaccines and not just for the production of immunogens. Vectors can be classified in three different categories: viral, bacterial, and plasmid [9] . Vectors can either be fully replicative or only cause abortive infection, still allowing the expression of the desired immunogens. They can be administered either parenterally or via mucosal membranes [10] . A major advantage of vector-based GM technology, is that the immunogens of interest are de novo synthesized, thus not only allowing for the induction of antibody and T helper cell mediated immunity, but also for the induction of protective cytotoxic T cell responses, mimicking a natural immune response against the immunogen. This balanced immune response opens pathways that were previously inaccessible with traditional vaccine technology using 'non-live' immunogens. Especially the induction of CD8+ CTL responses may be of particular interest for vaccines against certain virus infections and cancers [11] . Our previous study provides additional insights regarding the strengths, weaknesses, opportunities, and threats of such technology [12] .
In the present study, the potential of vector-based vaccines is evaluated. Data obtained from literature, granted patents, and different stage clinical trials are synthesised and analysed in the light of data from currently registered vaccines providing an overview of the potential of currently used and newly generated vectors in the field of vaccine development. The data suggest that vector-based vaccines may offer a cost-effective alternative for the production of safe vaccines against diseases for which no or less perfect vaccines exist today, thus catering for a huge unmet medical need.
Methodology
The methods applied in this study have been split in four different stages: evaluation of literature, patents, clinical trials, and registered GM and non-GM vaccines. Each stage was individually examined in detail and the complete data set was compiled. These stages were decided upon in order to provide a complete overview of the genetically modified (GM) vector-based vaccine pipeline and market.
Literature research
To map the early research stage of emerging vectors, a literature search was performed on available candidate vector vaccine studies. Data was collected on various types of GM vectors and their properties, as mentioned in both research publications and reviews. The search was conducted using a combination of Embase, Medline, Web-of-science, Pubmed, Cochrane, and Google Scholar. Medical Subject Headings (MeSH) and Boolean Operators were utilised in order to develop a basis for the syntax. The search was restricted to publications/translations in English. This syntax and the search results were analysed by an independent biomedical information specialist from Erasmus Medical Centre medical library. Additional information on the search terms for different search engines can be found in the supporting information (S1).
A total of 1756 hits were obtained [13] . 511 duplicates were removed, resulting in 1245 publications. Restrictions for further analysis included articles not describing vaccines or vaccine technologies, and articles not describing novel vaccine technologies. Publications were restricted to those published in the period 2009-2014. The total set contained 87 review articles on GM vaccines.
In order to retrieve more papers on vector-based GM vaccine candidates, an additional search was performed on Pubmed including relevant search terms ''vaccine", ''vector" and ''GM". Reviews were retrieved adding the search term ''review" to the previously mentioned terms or by searching for reviews only. Papers dating from the period 1998 to 2014 were collected and 18 new results were added to the previous 87 (Table 1) .
A total of 38 publications, specifically on the topic of vectorbased vaccines, were selected from this pool and analysed in detail. The clinical studies and reviews evaluated are shown in Table 2 , and the results of this literature study can be found in Table 6 .
Search for patents
Patents have multiple technology classifications based on their claims, and since they are classified in technological classes, patents related to GM vaccines were collected into a database. Patent data concerning GM vaccines was retrieved from Espacenet, which provides access to over 90 million patent documents worldwide [14] . Search terms used were ''Medicinal preparations containing antigens or antibodies", ''Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy" and ''Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefore", in combination with search words vaccin ⁄ (Boolean operator), and genetic ⁄ OR modif ⁄ , respectively. The results were deduplicated based on the priority numbers. The syntax and search results were analysed by a patent specialist from the Netherlands Enterprise Agency (RVO) [15] , a governmental institution in the department of Economic Affairs. A total number of 40.308 unique patents were found and an original database was created, including all classes and subclasses. As patent information in the patent database is condensed into Cooperative Patent Classification (CPC) codes, the previous search was repeated, combining the previous search with CPC codes for vectors and search term vaccine ⁄ . A total of 96 unique CPC codes were used, resulting in 32.738 vector-based vaccine patent documents. As CPC codes describe the classification in each technical area on various levels, the definitions of the CPC codes used were retrieved from Espacenet, and a comprehensive table was created including the CPC codes, their definitions, and the number patents containing this specific code. All search terms can be found in Table 3 . The results are illustrated in Fig. 1 and a complete overview of these CPC codes and their description can be found in the supporting information (S2). It should be noted that the Final set used for detailed analysis 38 method used for this search was iterative, the original data was used to reproduce search terms for the vector search. Because of this iterative method, a complete dataset was collected.
Search for clinical trials
Clinical trials data (phase 1, 2, and 3) was gathered from the World Health Organisation International Clinical Trials Registry Platform, which currently lists 191,038 studies in 190 countries (data retrieved: May 29th, 2015 [16] ). Search terms applied can be found in Table 4 . The results were deduplicated based on the Trial ID number. A total of 1146 unique clinical trials were used to create an original database.
To provide a detailed outlook on the use of viral vectors in GM vaccine trials, the clinical trials database was analysed in a vector specific way. The progress of vector-based vaccines as a share of all GM vaccines was examined, as well as the spread of specific vectors and their prevalence for specific indications. Data entries on vector trials were sorted by their indication and frequency, and the 10 most prevalent indications were selected to form a new data subset. This subset was analysed on the specific types of vectors used per indication, and a comparison was made for these indications with the complete dataset of all GM vaccines. The results are shown in Table 7 .
Search for registered GM and non-GM vaccines
Data concerning registered vaccines was obtained from governmental databases of the following regions; USA, EU, Brazil, India, China, South-Africa, Australia and Japan (Table 5 ). BRICS countries were selected (only four out of five BRICS countries were included, Russia being omitted due to the general inaccessibility of Russian registers), because of their rapidly growing economies and potential for the industry. Currently, a total number of 821 registered human vaccines are on the market. After deduplication, 797 registered vaccines remained, of which 124 related to GM vaccines. Boolean search terms used to classify vaccines were: ''Genet ⁄ ",
''VLP/Virus-like" and ''Virosome". In order to analyse the availability of vector-based vaccines on the market, an analysis was performed on this database on vaccines classified as vector-based.
Data convergence

Patents and clinical trials
In order to provide an overview on the prevalence of vectors that have been patented and/or registered for clinical trials, two more data analyses were performed. Initially, the comprehensive patent database, that was created as described above, was analysed for data on the specific vector types. This data was then combined with data on vector types from the clinical trial database.
Relevant patent entries were selected from our database based on the presence of CPC codes related to vectors in the patent application and a sub database was created, including 73 different vectors or vector combinations extracted from 10287 unique patents. As many of these vectors only appeared a few times, the top 21 of Table 2 List of clinical studies and reviews evaluated.
Altenburg et al. [48] Nébié et al. [ For the clinical trials analysis, a similar procedure was applied. Instead of searching for CPC codes, data on the technology class of the vaccine was extracted from the previously generated clinical trial database by searching the variable ''Expression System". Relevant data on vectors was extracted, resulting in 17 vectors in 117 phase 1 trials, 14 vectors in 66 phase 2 trials and 2 vectors in 2 phase 3 trials. The results of these analyses are shown in Fig. 3 .
Evolution of GM vaccines: convergence of all three data bases
In order to visualise the progress of GM vaccines over the years, a timeline was created using data from all available databases (patents, clinical trials, and registered) on the prevalence per indication per year. 16 Indications were selected based on their presence in all databases, and six indications were selected that were present in patents and clinical trials, albeit absent in registered. This resulted in a timeline of vaccine presence per year for 22 indications spanning from 1976 to 2013. Data on registered vaccines from India have been omitted from this analysis, as no information on the dates of application was given in Indian registers. Patents and clinical trials databases comprise of only GM vaccines. The registered database has been used in its entirety, both GM and non-GM vaccines. This visualisation is shown in Fig. 4 . Table 6 provides information on the most frequently used vectors, as mentioned in literature. In total 21 viral, 3 bacterial and 1 plasmid DNA vectors are presented in this table, covering the most essential vectors of each type for vaccine production or delivery. This table shows data on several upcoming vectors, which are being researched, e.g. new subtypes of poxviruses, adenoviruses, and novel bacterial vectors. Furthermore, the table comprises indications mentioned for these vectors, their advantages and challenges. The viral vector part covers general viral vector species, and several important main viral families followed by their relevant species. At this point, viral vectors have been researched in more detail than bacterial vectors. Poxviruses and adenoviruses are most frequently mentioned in literature. Moreover, details on the application of these two viral families and several of their species and subspecies, as vectors for vaccine development, are more common. As demonstrated in Table 7 , analysing clinical trials in detail shows that out of 762 GM vaccine trials, 198 are vector-based. This corresponds to a percentage of 26%. Indications with a high percentage for vector-based GM vaccine trials are variola (89%), epstein-barr (67%), HIV (56%), tuberculosis (TB) (42%), cancer (38%), and malaria (38%). Indications that have very little vectorbased trials are influenza (3%), human papillomavirus (HPV) (1%), and hepatitis B (1%). The most prominent vectors are the vaccinia virus (modified vaccinia Ankara (MVA) & New York strain (NYVAC), 36.3%) and adenoviruses (17.7%).
Results
Analysing the market
The cumulative frequency of the aforementioned vectors per year is shown in Fig. 2 . Results from this graph and table illustrate a significant increase in MVA and adenovirus application over the years, while growth of vaccines based on vaccinia virus, ALVAC, and fowlpox virus has stagnated.
The results from our registered vaccines search show that the first vector-based vaccine registered for use on the market is IMO-JEV (2010), a Japanese Encephalitis vaccine, based on a yellow fever virus (family Flaviviridae) vector [61] . The second is the tetravalent dengue vaccine, Dengvaxia (2015) comprising a Yellow Fever virus (YFV) encoding two JE viral proteins [62] .
Data convergence
The analysis of the prevalence of specific vectors in patents and clinical trials is presented in Fig. 3 . A total of 9088 vector-based vaccine patents were evaluated for the patent database. The orthopoxvirus (vaccinia/variola) is most prevalent with 2200 occur 
Discussion
This study provides an overview of the vector-based GM vaccine pipeline and market, indicating that poxviruses and adenoviruses are among the most prominent vectors in GM vaccine development. Our findings show that vector-based vaccines comprise a significant part of all GM vaccines (26%) in the pipeline.
To realise data completeness, four different stages of research were conducted and analysed in detail. These stages covered literature, patents, clinical trials, and the registered market of vectorbased GM vaccines, generating an idea of evolution these vaccines have gone through over the years. During the start of this project it became clear that GM vaccines have no unambiguous definition. (1, 2, or 3) ''DNA" ''Engineered" ''Expression system" ''Genetic" ''Genetically Engineered" ''Indication" ''Genetically Modified" ''Live" ''Production system" ''Live-attenuated" ''Modified" ''Specific target" ''Recombinant Protein" ''Recombinant" ''Technology Class" ''RNA" ''Vector" ''Virosome" ''Type of Organism" ''VLP" Total number of vaccines after deduplication 1146 Of which GM vaccines 762 Of which vector-based GM vaccines 226 [9, 27, 28, 35, 38, 46] (continued on next page) (continued on next page) Various search terms were often found in literature to define GM vaccines, nevertheless these terms were all used in an inconsistent manner. The definition of GM vaccines was narrowed down by delineation of search terms found in CPC codes and literature. Literature widely acknowledged that, compared to bacterial or DNA vectors, viral vectors have been researched in more detail (Table 6 ). Poxviruses and adenoviruses are referenced often and a lot of details are provided on the use of these families as viral vectors. Nevertheless, pre-existing immunity is still a major obstacle for several viral vectors (Table 6 ). This is of special concern for the use of adenovirus vectors, although several strategies to circumvent this problem have been developed [40, 44, 45, 64] . Interestingly there are many data suggesting that this seems to be les of a problem for MVA based vaccine candidates [65] [66] [67] .
In comparison with viral vectors, DNA and bacterial vectors show potential in this respect, but this require more research. Furthermore there are several other limitations to overcome. The primary limitation of bacterial vectors is their lack of immunogenicity compared with viral vectors [68] . In addition, viruses are relatively easier to work with, since they have less complex genome than bacteria [69] . Although several types of bacteria have been mentioned in literature (e.g. Escherichia coli, Vibrio cholerae, Mycobacteria, and Shigella spp.), these are not mentioned in the table due to lack of sufficient information on their advantages and disadvantages [39] . The results of the patent search show that the most prominent CPC codes in the patent database on vector-based vaccines cover general information on vectors (C12N15/79, A61K2039/5256, A61K2039/523). These CPC codes do not comprise specific vectors but are general indicators for vector-based vaccines. A large variety of different vector types are being patented for vaccine development (Fig. 1) . According to the patent database, both ''mastadenovirus" and ''orthopoxvirus: vaccinia/variola" are the most prominent vectors. Human adenoviruses are part of mastadenovirus genus, which in turn is a large genus of the adenoviridae family. It is notable that orthopoxvirus: vaccinia/variola as well as poxviridae appear in the patent results. The species vaccinia virus and variola virus are part of the genus orthopoxvirus, which belongs to the family of Poxviridae. The explanation behind this seemingly double occurrence is that CPC codes for both the species and the family are present in Espacenet. There is one CPC code for both vaccinia and variola combined, rather than a separate code for each of these species.
For clinical trials, vector-based vaccines play quite an important part in GM vaccine trials as a whole. 26% of all GM vaccine trials use vector-based candidate vaccines, especially for currently undefeated indications, such as cancer, HIV, TB, and malaria (Table 7) . Although no active clinical trials on malaria based on fowlpox vectors are provided in the clinical trials database (clinicaltrial.gov), literature shows that fowlpox vectors are being examined in combination with different vaccination regimens [70, 71] . Intervention strategies for these diseases represent a large unmet medical need, still causing over a million deaths every year [72] . With limited if any cure available, new methods might provide additional value to vaccine research and development, in hope for a breakthrough. This premise is confirmed by Fig. 4 . Cancer, HIV, and malaria show a large presence in both patent and clinical trial databases, while Hib, Hepatitis A, and meningococcus show little development in patent and clinical trials stages in recent years. This implies a lower need for new vaccine technologies for these indications, as current vaccines based on conventional methods are apparently sufficiently satisfactory [73] [74] [75] . Table 7 also shows that very little vector-based vaccine trials are present for more or less treatable diseases such as HPV induced neoplasias, hepatitis B, and influenza. Apparently there is less medical need for vector-based vaccines for these indications, as vaccine candidates are available based on GM-based and non-GM-based techniques [76] [77] [78] . There is, a significant amount of active non-vector-based GM trials for these three indications, demonstrating the variety of GM techniques applied in vaccine development. For influenza and hepatitis B vaccine production, the use of recombinant DNA technology is already common practice [6, 79] . Therefore, the focus of research is on optimising the technology used, rather than on investing in new vector-based technology research.
The increase in MVA vector usage compared to the use of vaccinia virus indicates that MVA has started to replace regular vaccinia virus in vector-based vaccine development, as vaccinia trials have stagnated while MVA trials are increasing rapidly (Fig. 2) . The reasons for this replacement is predominantly related to the safety and efficacy of MVA, as it only causes an abortive infection, while inducing an abundant expression of the target immunogen, leading to impressive protective immune responses [12] . The prominent use of adenoviruses as viral vectors is probably due to the considerable knowledge on this virus family, the ease of manipulation of the virus for use in vector-based vaccines, and the broad tissue tropism associated with this virus [40, 80] .
The consensus that both poxviruses and adenoviruses are important for vector-based GM vaccine research is also strengthened by data shown in Fig. 3 , indicating high prevalence of these vectors in both patents and clinical trials. For patents and the first two phases of clinical trials, both orthopoxviruses vaccinia virus (mentioned in combination with variola virus), and adenoviruses are well represented (though in patents adenoviruses are not mentioned directly, these are part of the Mastadenovirus genus).
While analysing this data set, it is important to keep in mind that the data bases used are snapshots of each phase of research and development pipeline. Patents are made public 18 months after submission, but when patents are retracted before this 18 months period, they disappear from Espacenet. Clinical trials only show active and on-going trials (hence the database starts in 1999). Discontinued or terminated trials are removed from the database, consequently, making direct correlations between databases unjustifiable. Therefore, the analyses conducted in this study are not directly between databases but each database is seen as an individual snapshot.
Even though numerous vectors are being studied in different phases of pre-clinical and clinical research, the presence of their majority in phase 1 indicates that the evolution of vector-based vaccines has only just begun. The large amount of vector types being patented, or having reached phase 1 clinical trials, show a lot of promise, as new techniques might lead to a new generation of safer, more efficient, and cost-effective vaccines.
Comparing the data presented with the literature study we conducted initially, it seems that a lot of new vectors are being patented while little published information is available. This could indicate that some vectors are being patented beforehand, not necessarily in order to start a new study, but in case a method or technique is developed to make them suitable for vaccine production. Without patents, anyone could start developing these vectors without legal consequences, leading to companies competing to sell the vaccine for the lowest price possible. When revenues from vaccine sales eventually do not lead to return on investment for past and future research and development there would be no incentive for the development of new generations of vaccines. Therefore the use of a patent search was considered a valid and valuable approach to gather part of our dataset.
In conclusion, our data suggest that although currently there are two licensed, vector-based human vaccine on the market and that this field is still in its early days, vector-based vaccines may offer a cost-effective alternative for the production of safe and effective vaccines against diseases for which no or less perfect vaccines exist today. The most promising vectors for vaccine development at this moment appear to be poxvirus and adenovirus vectors. This may be concluded for their abundant use in the development of vaccines against diseases like HIV-AIDS, malaria, tuberculosis and different forms of neoplastic disease. It may be expected that the current efforts spent on developing vectorbased vaccines, may lead to promising vaccine candidates for these indications and therefore hold promise for current and future unmet medical needs. Therefore, after the recent eradication of smallpox using Jenner's vaccinia virus as the first vaccine, this and other viruses may now be the basis for constructing vectors that may help us control other major scourges of mankind.
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